UNCY

Over the past six months, Unicycive Therapeutics' stock price has decreased by 26%. Key events include a securities class action lawsuit filed on September 3, 2026, alleging federal securities law violations related to public statements about its oxylanthanum carbonate new drug application. The company received a second FDA Complete Response Letter (CRL) for its New Drug Application (NDA) for oxylanthanum carbonate due to deficiencies at a third-party manufacturing vendor, following a previous CRL for similar reasons. Unicycive Therapeutics announced the resubmission of its NDA for oxylanthanum carbonate on September 29, 2026. On October 1, 2026, Meredith Manning was appointed to the company's Board of Directors. In terms of earnings, the company reported a Q2 2026 loss of -$0.06 per share, exceeding analysts' expectations, but Q1 2026 earnings per share were -$0.54, missing estimates.